“Underpowered” Trials Unethical Unless In Early Phase Or Meta-Study – JAMA
This article was originally published in The Gray Sheet
Executive Summary
Early-phase, "underpowered" clinical trials of devices or drugs can be considered ethical only if designed to guide later pivotal studies, Scott Halpern, University of Pennsylvania School of Medicine, et al., write in the July 17 Journal of the American Medical Association
You may also be interested in...
Medtronic InSync ICD Gains Panel Support In Tiebreaking 6-5 Vote
The recommended post-market requirement for Medtronic's InSync ICD and its pacing counterpart suggests that companies that conduct pivotal studies with a small number of patients will be expected to follow up with a large trial
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.